West Pharmaceutical Services, Inc. (WST) Financial Statements
Historical financial data — 42 statements covering FY2016–FY2025
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging componen...
West Pharmaceutical Services, Inc.'s revenue increased 6.3% year over year, from $2.89B to $3.07B.
Net income increased 0.2% over the same period, from $492.7M to $493.7M.
Over the 9-year period from FY2016 to FY2025, revenue grew by 104% in total.
Total debt remained relatively stable at $202.8M.
The debt-to-equity ratio stands at 0.06, indicating a conservative leverage profile.
Operating cash flow grew 15.5% to $754.8M.
West Pharmaceutical Services, Inc. maintains a healthy net profit margin of 16.1%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2024 | $746.9M+6.4% | $136.0M | $264.7M | $161.3M | $180.1M | $3.68B | $202.6M | $2.75B |
| Q4 FY2024 | $748.8M+0.3% | $130.1M | $273.6M | $159.6M | $190.1M | $3.64B | $202.6M | $2.68B |
| Q1 FY2025 | $698.0M-6.8% | $89.8M | $231.9M | $107.0M | $129.4M | $3.62B | $202.6M | $2.68B |
| Q2 FY2025 | $766.5M+9.8% | $131.8M | $273.9M | $153.7M | $177.1M | $3.95B | $202.6M | $2.93B |
| Q3 FY2025 | $804.6M+5.0% | $140.0M | $294.3M | $167.6M | $197.2M | $4.11B | $202.7M | $3.05B |
| Q4 FY2025 | $805.0M+0.0% | $132.1M | $303.9M | $156.6M | $251.1M | $4.27B | $202.8M | $3.18B |
| Q1 FY2026 | $844.9M+5.0% | $138.8M | $296.4M | $177.1M | $89.9M | N/A | N/A | N/A |
| Q2 FY2026 | $872.3M+3.2% | $154.0M | $329.2M | $179.1M | $124.0M | N/A | N/A | N/A |
Balance Sheet Summary (FY2025)
West Pharmaceutical Services, Inc. (WST) Financial Statements & Revenue History
West Pharmaceutical Services, Inc. (WST) is a US-listed stock operating in the Healthcare sector, specifically the Surgical & Medical Instruments & Apparatus industry trading at $384.02 with a market capitalization of $27. This page provides 42 historical financial statements for West Pharmaceutical Services, Inc., including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, West Pharmaceutical Services, Inc. reported revenue of $3.1 billion, representing 6.3% year-over-year growth. The net profit margin of 16.1% reflects strong profitability. The debt-to-equity ratio of 0.06 shows conservative leverage.
WST Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows West Pharmaceutical Services, Inc.'s revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether WST is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track WST's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently West Pharmaceutical Services, Inc. converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of WST's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use WST Financial Data
Investors use West Pharmaceutical Services, Inc.'s financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare WST's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how WST's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View WST's financial health score, earnings, and pre-market pricing.
Financial data is sourced from West Pharmaceutical Services, Inc.'s SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.WST trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.